Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB3 | P54753 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 6/20 | 0.44 |
| ▸ | RAB9A | P51151 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD4 | P21917 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1290436 | 0.87 | EPHB3 (0.58) | EPHB3MAPK1NPC1RAB9AALDH1A1 | |
| SCHEMBL22259354 | 0.82 | EPHB3 (0.45) | EPHB3MAPK1NPC1RAB9AALDH1A1 | |
| SCHEMBL7373294 | 0.80 | MAPK1 (0.44) | EPHB3MAPK1NPC1RAB9AALDH1A1 | |
| SCHEMBL18412881 | 0.77 | DRD2 (0.42) | EPHB3MAPK1NPC1RAB9AALDH1A1 | |
| SCHEMBL21236685 | 0.76 | EPHB3 (0.46) | EPHB3NPC1RAB9ALMNAHTT | |
| SCHEMBL24612190 | 0.74 | ALDH1A1 (0.40) | EPHB3MAPK1NPC1RAB9AALDH1A1 | |
| SCHEMBL1286674 | 0.72 | NPC1 (0.68) | EPHB3NPC1RAB9AALDH1A1HPGD | |
| SCHEMBL21893810 | 0.72 | EPHB3 (0.43) | EPHB3NPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL3079162 | 0.71 | EPHB3 (0.43) | EPHB3NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL7308374 | 0.71 | HTR3E (0.51) | MAPTSMN1; SMN2LMNAHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2176260-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-04-21 | — | — | EP | claimed |
| WO-2009008748-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-01-15 | — | — | WO | claimed |
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-09-09 | — | — | US | disclosed |
| EP-2176260-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009008748-A1 | PYRAZOLO[1,5-A]PYRIDINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-01-15 | — | — | WO | disclosed |
| EP-0368343-A2 | Ameliorating composition for dysmnesia | KYORIN SEIYAKU KABUSHIKI KAISHA (JP) | 1990-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100226881-A1 | PYRAZOLO[1,5-a]PYRIDINES AND THEIR USE IN CANCER THERAPY | TP53, PNPO, DPYD | EPHB3 2757/4885MAPK1 602/4885NPC1 3271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.